VRDN Insider Trading - Viridian Therapeutics, Inc.

Utestående aktier	81,668,033 shares
Insideraktier	19 061 167 shares
Insynsägande	23,34 %
Totalt antal insynspersoner	51

Insider Sentiment Score

Insider sentiment score hittar de företag som köps av foretagsinsynspersoner.

Det är resultatet av en sofistikerad, kvantitativ multifaktormodell som identifierar företag med de högsta nivåerna av insiderackumulation. Poängmodellen använder en kombination av nettoantalet insiders som köpt de föregående 90 dagarna, det totala antalet aktier som köpts i procent av aktiekapitalet och det totala antalet aktier som ägs av insiders. Siffran sträcker sig från 0 till 100, med högre siffror som indikerar en högre nivå av ackumulering för sina kamrater, och 50 är genomsnittet.

Uppdateringsfrekvens: Dagligen

Se Insiders Top Picks, som ger en lista över företag med högsta insiderackumulation.

Se Högst rankade aktier

Office Sentiment Score

Officersentiment Score hittar företag som köps av Corporate Officers.

Per definition Corporate Officers är Corporate Insiders, men till skillnad från vissa av de andra Insiders (10 % aktieägare och styrelseledamöter), arbetar ämbetsmän för företaget dagligen och de använder sina egna pengar när de handlar . (10 % aktieägare och styrelseledamöter är ofta fondförvaltare som förvaltar andras pengar.) Som sådan är insideraffärer som görs av tjänstemän mycket mer betydelsefulla och bör behandlas på lämpligt sätt.

Liksom Insider Sentiment Score är Officer Sentiment Score resultatet av en sofistikerad, kvantitativ multifaktormodell som identifierar företag med de högsta nivåerna av officersackumulering.

Uppdateringsfrekvens: Dagligen

Se insiderns bästa val, vilket ger en lista över företag med högsta insider sentiment.

Se Högst rankade aktier

Viktiga insidernyckeltal

Denna kort visar hur företaget rankas längs olika insidernyckeltal. Procenttilrankningen visar hur detta företag jämförs med andra företag på USA-marknaden. Högre rankingar indikerar bättre situationer.

Till exempel anses det allmänt att insiderköp är en positiv indikator, så företag med mer insiderköp skulle rankas högre än företag med mindre insiderköp (eller til och med insiderförsäljning).

Nettoantalet insiders som köper (rankning)

0 ( )

2173 out of 11275

Nettoantalet insiders som köper är den totala mängden insiders som säljer minus det totala antalet insiders som säljer under de senaste 90 dagarna. Percentilrankningen visas här (intervall från 0 till 100%).

Procent av flytande köpta av insiders (ranking)

0.000 %( )

2186 out of 11219

Procentandelen av aktier köpta av insiders är det totala antalet aktier som köpts av insiders minus det totala antalet aktier som sålts av insiders under de senaste 90 dagarna, dividerat med det totala antalet aktier och multiplicerat med 100.

Insiderhandelsdiagram

Viridian Therapeutics, Inc. insideraffärer visas i följande diagram. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. I allmänhet är det i allmänhet olagligt för insiders att göra affärer i sina företag baserat på väsentlig, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4.

Insiderlista och lönsamhetsstatistik

Den här tabellen visar listan över kända insiders och genereras automatiskt från anmälningar som avslöjas till SEC. Förutom namnen, den senaste titeln och direktören, tjänstemannen eller ägarbeteckningen på 10 %, tillhandahåller vi de senaste avslöjade innehaven. Dessutom, när det är möjligt tillhandahåller vi insiderns historiska handelsresultat. Det historiska handelsresultatet är ett vägt genomsnitt av resultatet för faktiska köptransaktioner på den öppna marknaden som insidern gjort. För mer information om hur detta beräknas, titta på detta YouTube-webinarium.

See our leaderboard of most profitable insider traders.

Insider	Aktier Ägda	Delad Justerad
Atlas Venture Fund VII L P 10% Owner - [10%]	6 285 160	419 011
Beetham Thomas W. Chief Operating Officer - [O]	6 000	6 000
Bruce Booth Director - [D]	1 351 090	90 073
Christopher Bowden	24 000
Cohen Steven A/sac Capital Mgmt Lp 10% Owner - [10%]	426 162	426 162
Thomas Ciulla Chief Medical Officer - [O]	762	762
John W Creecy Director - [D]	5 413 126	360 875
Diana Escolar	270 000
Fhmlsp, L.l.c. 10% Owner - [10%]	1 505 200	1 505 200
Fhmlsp, L.p. 10% Owner - [10%]	1 505 200	1 505 200
Fairmount Funds Management LLC Director, 10% Owner - [D] [10%]	3 459 913	3 459 913
Fairmount Healthcare Fund GP LLC Director - [D]	938 233	1 845 813
Fairmount Healthcare Fund II GP LLC Director - [D]	938 233	3 459 913
Fairmount Healthcare Fund II L.P. Director - [D]	938 233	3 459 913
Fairmount Healthcare Fund L.P. Director - [D]	938 233	1 845 813
Frazier Life Sciences Public Fund, L.P. 10% Owner - [10%]	1 505 200	1 505 200
David A Gonyer Director - [D]	1 899	1 899

Insider	Aktier Ägda	Delad Justerad
Peter Evan Harwin	24 000
Hatfield Jeffrey S.	24 000
Hughes Thomas E. Director - [D]	12 827	855
Kristian Humer	90 000
Robert Brian Johnson	0
Kevin Koch	24 000
Barrett Katz Chief Medical Officer - [O]	0	0
Tomas Kiselak	24 000
Peter Kolchinsky 10% Owner - [10%]	410 686	410 686
Alpha, Lllp Lebow 10% Owner - [10%]	4 465 258	4 465 258
Bennett S Lebow Director, 10% Owner - [D] [10%]	280 600	18 707
Kyle Lefkoff Director - [D]	463 473	30 898
Leverone Jason A. CFO, Treasurer & Secretary - [O]	48 829	3 255
Adam Scott Levy Chief Business Officer - [O]	10 540	703
Logos Global Master Fund LP 10% Owner - [10%]	6 000 000	6 000 000
Mahoney Stephen F. President and CEO, Director - [D] [O]	21 400	21 400
William Stuart Marshall President & CEO, Director - [D] [O]	270 646	18 043

Insider	Aktier Ägda	Delad Justerad
Lara Meisner Chief Legal Officer - [O]	29 971	29 971
Arlene Morris	24 000
Scott Dunseth Myers Chief Executive Officer, Director - [D] [O]	259 500	259 500
Point72 Asset Management, L.P. 10% Owner - [10%]	426 162	426 162
Point72 Capital Advisors, Inc. 10% Owner - [10%]	426 162	426 162
Ra Capital Management, Llc 10% Owner - [10%]	410 686	410 686
RA Capital Healthcare Fund LP 10% Owner - [10%]	410 686	410 686
Paul D Rubin	87 000
Rauch Lee M.	900 000
Remeditex Ventures LLC 10% Owner - [10%]	5 413 126	360 875
Samuel D Riccitelli President & CEO, Director - [D] [O]	571 370	571 370
Tamara A Seymour CFO, Secretary, Treasurer - [O]	106 447	106 447
Douglas A Schuling Director - [D]	10 500	10 500
Shah Rajeev M. 10% Owner - [10%]	410 686	410 686
Robin L Smith Director - [D]	1 900	1 900
Joseph L Turner	24 000
Jonathan Violin Chief Executive Officer, Director - [D] [O]	480 905	480 905

Report errors via our new Insider Auditing Tool

Track Records av insiderköp - Kortsiktig vinstanalys

I denna sektion analyserar vi lönsamheten för varje oplanerat, öppet-marknads insiderköp gjorda i VRDN / Viridian Therapeutics, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormala avkastningar och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .

Tabellen nedan visar de senaste köpen på öppna marknaden som inte var en del av en automatisk handelsplan.

Handelsdatum	Insider	Rapporterade aktier	Rapporterat pris	Justerade aktier	Justerat pris	Kostnadsbasis	Dagar til Max	Pris vid Max	Maximal vinst ($)	Maximal avkastning (%)
2024-09-27	Mahoney Stephen F.	21 400	23,3300	21 400	23,3300	499 262	45	25.7100	50 932	10,20
2024-09-27	Beetham Thomas W.	5 000	23,4100	5 000	23,4100	117 050
2024-09-13	Fairmount Funds Management LLC	1 600 000	18,7500	1 600 000	18,7500	30 000 000
2024-01-22	Fairmount Funds Management LLC	476 190	21,0000	476 190	21,0000	9 999 990
2023-04-12	Myers Scott Dunseth	4 000	25,3697	4 000	25,3697	101 479
2023-03-13	Myers Scott Dunseth	5 500	29,1499	5 500	29,1499	160 324
2022-08-17	Fairmount Funds Management LLC	425 531	23,5000	425 531	23,5000	9 999 978
2021-09-23	Frazier Life Sciences Public Fund, L.P.	200 000	11,0000	200 000	11,0000	2 200 000
2021-09-21	Fairmount Funds Management LLC	909 000	11,0000	909 000	11,0000	9 999 000

Justeringar av aktierär de justerade aktierna efter justerat pris. Justeringar av aktierär de justerade aktierna efter uppdelning.

VRDN / Viridian Therapeutics, Inc. Insider Trades

Track Records av insiderförsäljning - Kortsiktig förlustanalys

Tabellen nedan visar de senaste försäljningarna på öppna marknaden som inte var en del av en automatisk handelsplan.

Handelsdatum	Insider	Rapporterade aktier	Rapporterat pris	Justerade aktier	Justerat pris	Kostnadsbasis	Dagar til Min	Pris vid Min	Maximal förlust undvikits ($)	Maximal förlust undvikits ($)
2023-06-16	Meisner Lara	27	28,3500	27	28,3500	765	129	11.1200	−465	−60,75
2023-06-06	Meisner Lara	5 126	25,0200	5 126	25,0200	128 253
2023-06-05	Meisner Lara	499	25,0300	499	25,0300	12 490
2023-02-02	Violin Jonathan	50 000	36,8000	50 000	36,8000	1 840 000
2023-02-02	Violin Jonathan	50 000	36,8000	50 000	36,8000	1 840 000
2022-06-01	Violin Jonathan	30 000	12,2000	30 000	12,2000	366 000
2022-05-02	Violin Jonathan	30 000	13,0400	30 000	13,0400	391 200
2022-04-04	Violin Jonathan	3 600	18,9300	3 600	18,9300	68 148
2022-04-01	Violin Jonathan	26 400	18,9200	26 400	18,9200	499 488

Justeringar av aktierär de justerade aktierna efter justerat pris. Justeringar av aktierär de justerade aktierna efter uppdelning.

Transaktionshistorik

Klicka på länkikonen för att se hela transaktionshistoriken. Transaktioner som rapporteras som en del av en automatisk handelsplan 10b5-1 kommer att ha ett X i kolumnen markerad 10b-5.

Fil datum	Handel datum	Schema	Insider	Ticker	Värdepappertitel	Kod	Direkta	Utövningspris	Enhet pris	Enheter ändrad	Värde ändrad (1K)	Kvarvarande Optioner	Kvarvarande Aktier
2025-06-11	2025-06-10	4	Fairmount Funds Management LLC Fairmount Healthcare Fund II LP	VRDN	Common Stock	M - Exercise	I		12,3100	12 500	154		3 459 913
2025-06-11	2025-06-09	4	Fairmount Funds Management LLC Fairmount Healthcare Fund II LP	VRDN	Common Stock	M - Exercise	I		7,8000	1 600	12		3 447 413
2024-09-30	2024-09-27	4	Beetham Thomas W.	VRDN	Common Stock	P - Purchase	D		23,4100	5 000	117		6 000
2024-09-30	2024-09-27	4	Mahoney Stephen F.	VRDN	Common Stock	P - Purchase	D		23,3300	21 400	499		21 400
2024-09-17	2024-09-13	4	Fairmount Funds Management LLC Fairmount Healthcare Fund II LP	VRDN	Common Stock	P - Purchase	I		18,7500	1 600 000	30 000		3 445 813
2024-04-01	2024-03-28	4	Fairmount Funds Management LLC Fairmount Healthcare Fund II LP	VRDN	Common Stock	J - Other	I			5 859			1 845 813
2024-04-01	2024-03-28	4	Fairmount Funds Management LLC Fairmount Healthcare Fund LP	VRDN	Common Stock	J - Other	I			−5 859			0
2024-01-24	2024-01-22	4	Fairmount Funds Management LLC Fairmount Healthcare Fund II LP	VRDN	Common Stock	P - Purchase	I		21,0000	476 190	10 000		1 839 954
2024-01-12		3	Ciulla Thomas	VRDN	Common Stock		D						762
2023-06-20	2023-06-16	4	Meisner Lara	VRDN	Common Stock	S - Sale	D		28,3500	−27	−1		29 971
2023-06-20	2023-06-16	4	Meisner Lara	VRDN	Common Stock	M - Exercise	D		23,0300	27	1		29 998
2023-06-20	2023-06-15	4	Meisner Lara	VRDN	Common Stock	S - Sale	D		28,0200	−2 269	−64		29 971
2023-06-20	2023-06-15	4	Meisner Lara	VRDN	Common Stock	M - Exercise	D		23,0300	2 269	52		32 240
2023-06-06	2023-06-06	4	Meisner Lara	VRDN	Common Stock	S - Sale	D		25,0200	−5 126	−128		29 971
2023-06-06	2023-06-06	4	Meisner Lara	VRDN	Common Stock	M - Exercise	D		18,5100	5 126	95		35 097
2023-06-06	2023-06-05	4	Meisner Lara	VRDN	Common Stock	S - Sale	D		25,0300	−499	−12		29 971
2023-06-06	2023-06-05	4	Meisner Lara	VRDN	Common Stock	M - Exercise	D		18,5100	499	9		30 470
2023-06-06	2023-06-02	4	Meisner Lara	VRDN	Common Stock	S - Sale	D		24,2100	−1 875	−45		29 971
2023-06-06	2023-06-02	4	Meisner Lara	VRDN	Common Stock	M - Exercise	D		14,0000	1 875	26		31 846
2023-04-12	2023-04-12	4	Myers Scott Dunseth	VRDN	Common Stock	P - Purchase	D		25,3697	4 000	101		259 500
2023-03-13	2023-03-13	4	Myers Scott Dunseth	VRDN	Common Stock	P - Purchase	D		29,1499	5 500	160		255 500
2023-03-10	2023-03-09	4	Meisner Lara	VRDN	Common Stock	S - Sale	D		29,0700	−29 971	−871		0
2023-02-07	2023-02-06	4	Myers Scott Dunseth	VRDN	Common Stock	A - Award	D			250 000			250 000
2023-02-07	2023-02-02	4/A	Violin Jonathan	VRDN	Common Stock	S - Sale	D		36,8000	−50 000	−1 840		480 905
2023-02-07	2023-02-02	4/A	Violin Jonathan	VRDN	Common Stock	M - Exercise	D		0,1500	50 000	8		530 905
2023-02-03	2023-02-02	4	Violin Jonathan	VRDN	Common Stock	S - Sale	D		36,8000	−50 000	−1 840		430 905
2023-01-25	2023-01-23	4	Meisner Lara	VRDN	Common Stock	S - Sale	D		35,6600	−6 843	−244		0
2023-01-25	2023-01-23	4	Meisner Lara	VRDN	Common Stock	M - Exercise	D		14,0000	1 872	26		6 843
2023-01-25	2023-01-23	4	Meisner Lara	VRDN	Common Stock	M - Exercise	D		23,0300	4 971	114		4 971
2023-01-18	2023-01-17	4	Katz Barrett	VRDN	Common Stock	S - Sale	D		37,2100	−24 853	−925		0
2023-01-18	2023-01-17	4	Katz Barrett	VRDN	Common Stock	M - Exercise	D		23,0300	24 853	572		24 853
2023-01-18	2023-01-13	4	Katz Barrett	VRDN	Common Stock	S - Sale	D		37,0100	−4 147	−153		0
2023-01-18	2023-01-13	4	Katz Barrett	VRDN	Common Stock	M - Exercise	D		23,0300	4 147	96		4 147
2023-01-11	2023-01-10	4	Katz Barrett	VRDN	Common Stock	S - Sale	D		35,3000	−47 377	−1 672		0
2023-01-11	2023-01-10	4	Katz Barrett	VRDN	Common Stock	M - Exercise	D		23,0300	47 377	1 091		47 377
2023-01-11	2023-01-09	4	Katz Barrett	VRDN	Common Stock	S - Sale	D		33,0400	−12 623	−417		0
2023-01-11	2023-01-09	4	Katz Barrett	VRDN	Common Stock	M - Exercise	D		23,0300	12 623	291		12 623
2022-12-22	2022-12-21	4	Meisner Lara	VRDN	Common Stock	S - Sale	D		29,1900	−16 326	−477		0
2022-12-22	2022-12-21	4	Meisner Lara	VRDN	Common Stock	M - Exercise	D		23,0300	16 326	376		16 326
2022-12-22	2022-12-20	4	Meisner Lara	VRDN	Common Stock	S - Sale	D		28,0700	−600	−17		0
2022-12-22	2022-12-20	4	Meisner Lara	VRDN	Common Stock	M - Exercise	D		23,0300	600	14		600
2022-12-19	2022-12-16	4	Meisner Lara	VRDN	Common Stock	S - Sale	D		28,4400	−1 297	−37		0
2022-12-19	2022-12-16	4	Meisner Lara	VRDN	Common Stock	M - Exercise	D		23,0300	1 297	30		1 297
2022-12-19	2022-12-15	4	Meisner Lara	VRDN	Common Stock	S - Sale	D		28,0800	−300	−8		0
2022-12-19	2022-12-15	4	Meisner Lara	VRDN	Common Stock	M - Exercise	D		23,0300	300	7		300
2022-12-14	2022-12-14	4	Meisner Lara	VRDN	Common Stock	S - Sale	D		28,1200	−15 656	−440		0
2022-12-14	2022-12-14	4	Meisner Lara	VRDN	Common Stock	M - Exercise	D		23,0300	15 656	361		15 656
2022-12-14	2022-12-12	4	Meisner Lara	VRDN	Common Stock	S - Sale	D		28,0500	−600	−17		0
2022-12-14	2022-12-12	4	Meisner Lara	VRDN	Common Stock	M - Exercise	D		23,0300	600	14		600
2022-11-16	2022-11-15	4	Meisner Lara	VRDN	Common Stock	S - Sale	D		22,0500	−8 125	−179		0
2022-11-16	2022-11-15	4	Meisner Lara	VRDN	Common Stock	M - Exercise	D		14,0000	8 125	114		8 125
2022-08-19	2022-08-17	4	Fairmount Funds Management LLC Fairmount Healthcare Fund II LP	VRDN	Common Stock	P - Purchase	I		23,5000	425 531	10 000		1 363 764
2022-06-02	2022-06-01	4	Violin Jonathan	VRDN	Common Stock	S - Sale	D		12,2000	−30 000	−366		480 905
2022-05-04	2022-05-02	4	Violin Jonathan	VRDN	Common Stock	S - Sale	D		13,0400	−30 000	−391		510 905
2022-04-05	2022-04-04	4	Violin Jonathan	VRDN	Common Stock	S - Sale	D		18,9300	−3 600	−68		540 905
2022-04-05	2022-04-01	4	Violin Jonathan	VRDN	Common Stock	S - Sale	D		18,9200	−26 400	−499		544 505
2022-03-03	2022-03-02	4	Violin Jonathan	VRDN	Common Stock	S - Sale	D		17,3600	−11 106	−193		570 905
2022-03-03	2022-03-01	4	Violin Jonathan	VRDN	Common Stock	S - Sale	D		17,8200	−18 894	−337		582 011
2022-02-03	2022-02-02	4	Humer Kristian	VRDN	Stock Option (Right to Buy)	A - Award	D	18,51		90 000		90 000
2022-02-03	2022-02-02	4	Katz Barrett	VRDN	Stock Option (Right to Buy)	A - Award	D	18,51		110 000		110 000
2022-02-03	2022-02-02	4	Meisner Lara	VRDN	Stock Option (Right to Buy)	A - Award	D	18,51		90 000		90 000
2022-02-03	2022-02-03	4	Violin Jonathan	VRDN	Common Stock	S - Sale	D		19,1600	−909	−17		600 905
2022-02-03	2022-02-02	4	Violin Jonathan	VRDN	Stock Option (Right to Buy)	A - Award	D	18,51		280 000		280 000
2022-02-03	2022-02-02	4	Violin Jonathan	VRDN	Common Stock	S - Sale	D		18,4700	−12 340	−228		601 814
2022-02-03	2022-02-01	4	Violin Jonathan	VRDN	Common Stock	S - Sale	D		19,5500	−16 751	−327		614 154
2022-01-03	2021-12-31	4	Humer Kristian	VRDN	Stock Option (Right to Buy)	A - Award	D	19,77		121 371		121 371
2021-12-10	2021-12-08	4	Violin Jonathan	VRDN	Series A Non-Voting Convertible Preferred Stock	C - Conversion	D			−9 413		0
2021-12-10	2021-12-08	4	Violin Jonathan	VRDN	Common Stock	C - Conversion	D			627 564			630 905
2021-09-28	2021-09-23	4	Frazier Life Sciences Public Fund, L.P.	VRDN	Common Stock	P - Purchase	D		11,0000	200 000	2 200		1 505 200
2021-09-23	2021-09-21	4	Fairmount Funds Management LLC Fairmount Healthcare Fund II LP	VRDN	Common Stock	P - Purchase	I		11,0000	909 000	9 999		938 233
2021-08-26		3	FHMLSP, L.P.	VRDN	Common Stock		D						1 305 200
2021-07-27	2021-07-26	4	Humer Kristian	VRDN	Stock Option (Right to Buy)	A - Award	D	17,09		360 000		360 000
2021-07-15	2021-07-14	4	Moses Jennifer K.	VRDN	Stock Option (Right to Buy)	A - Award	D	17,88		25 000		25 000
2021-06-16	2021-06-03	4	Kiselak Tomas	VRDN	Stock Option (Right to Buy)	A - Award	D	16,60		12 500		12 500
2021-06-16	2021-06-03	4	Harwin Peter Evan	VRDN	Stock Option (Right to Buy)	A - Award	D	16,60		12 500		12 500
2021-06-16	2021-06-03	4	Morris Arlene	VRDN	Stock Option (Right to Buy)	A - Award	D	16,60		12 500		12 500
2021-02-08	2021-02-04	4	TURNER JOSEPH L	VRDN	Director Stock Option (Right to Buy)	A - Award	D	20,50		25 000		25 000
2021-02-08	2021-02-04	4	Harwin Peter Evan	VRDN	Director Stock Option (Right to Buy)	A - Award	D	20,50		25 000		25 000
2021-02-08	2021-02-04	4	Hatfield Jeffrey S.	VRDN	Director Stock Option (Right to Buy)	A - Award	D	20,50		25 000		25 000
2021-02-08	2021-02-04	4	Kiselak Tomas	VRDN	Director Stock Option (Right to Buy)	A - Award	D	20,50		25 000		25 000
2021-02-08	2021-02-04	4	Morris Arlene	VRDN	Director Stock Option (Right to Buy)	A - Award	D	20,50		25 000		25 000
2021-01-21	2021-01-18	4	Katz Barrett	VRDN	Employee Stock Option (right to buy)	A - Award	D	23,03		356 000		356 000
2021-01-20	2021-01-18	4	Leverone Jason A.	VRDN	Employee Stock Option (right to buy)	A - Award	D	23,03		311 785		311 785
2021-01-20	2021-01-18	4	Violin Jonathan	VRDN	Employee Stock Option (right to buy)	A - Award	D	23,03		800 075		800 075
2021-01-19	2021-01-18	4	Rauch Lee M.	MGEN	Employee Stock Option (right to buy)	A - Award	D	23,03		15 000		15 000
2020-12-17		3	Shah Rajeev M.	MGEN	Common Stock		I						410 686
2020-11-20		3	COHEN STEVEN A/SAC CAPITAL MGMT LP See footnotes	MGEN	Common Stock		I						426 162
2020-11-16	2020-11-13	4	Logos Global Master Fund LP	MGEN	Common Stock	P - Purchase	D		14,8389	126 667	1 880		550 000
2020-11-16	2020-11-09	4	Logos Global Master Fund LP	MGEN	Common Stock	P - Purchase	D		1,1641	100 000	116		6 350 000
2020-11-16	2020-11-09	4	Logos Global Master Fund LP	MGEN	Common Stock	P - Purchase	D		1,0979	250 000	274		6 250 000
2020-11-16		3	Logos Global Master Fund LP	MGEN	Common Stock		D						6 000 000
2020-10-30	2020-10-27	4	Violin Jonathan	MGEN	Series A Non-Voting Convertible Preferred Stock	J - Other	D			9 413		9 413
2020-10-30	2020-10-27	4	Violin Jonathan	MGEN	Employee Stock Option (Right to Buy)	J - Other	D	0,01		4 338 079		4 338 079
2020-10-30	2020-10-27	4	Violin Jonathan	MGEN	Common Stock	J - Other	D			50 124			50 124
2020-10-30		3	Violin Jonathan	MGEN	Common Stock		D						50 124
2020-10-30	2020-10-30	4	Fairmount Funds Management LLC Fairmount Healthcare Fund II LP	MGEN	Series A Non-Voting Convertible Preferred Stock	P - Purchase	I		465,9600	28 843	13 440	111 192
2020-10-30	2020-10-30	4	Fairmount Funds Management LLC Fairmount Healthcare Fund LP	MGEN	Series A Non-Voting Convertible Preferred Stock	P - Purchase	I		465,9600	5 494	2 560	21 999
2020-10-30		3	Fairmount Healthcare Fund II L.P. By funds	MGEN	Common Stock		I						526 393
2020-10-29	2020-10-27	4	Kiselak Tomas	MGEN	Director Stock Option (Right to Buy)	A - Award	D	0,52		24 000		24 000
2020-10-29	2020-10-27	4	Harwin Peter Evan	MGEN	Director Stock Option (Right to Buy)	A - Award	D	0,52		24 000		24 000
2020-10-29	2020-10-27	4	Fairmount Funds Management LLC Fairmount Healthcare Fund II LP	MGEN	Series A Non-Voting Convertible Preferred Stock	J - Other	I			82 349		82 349
2020-10-29	2020-10-27	4	Fairmount Funds Management LLC Fairmount Healthcare Fund LP	MGEN	Series A Non-Voting Convertible Preferred Stock	J - Other	I			16 505		16 505
2020-10-29	2020-10-27	4	Fairmount Funds Management LLC Fairmount Healthcare Fund II LP	MGEN	Common Stock	J - Other	I			438 502			438 502
2020-10-29	2020-10-27	4	Fairmount Funds Management LLC Fairmount Healthcare Fund LP	MGEN	Common Stock	J - Other	I			87 891			87 891
2020-09-17	2020-09-13	4/A	Rauch Lee M.	MGEN	Stock Option (right to buy)	A - Award	D	0,91		900 000		900 000
2020-09-15	2020-09-14	4	Rauch Lee M.	MGEN	Stock Option (right to buy)	A - Award	D	0,91		900 000		900 000
2020-05-22	2020-05-21	4	Hatfield Jeffrey S.	MGEN	Stock Option (right to buy)	A - Award	D	0,63		24 000		24 000
2020-05-22	2020-05-21	4	TURNER JOSEPH L	MGEN	Stock Option (right to buy)	A - Award	D	0,63		24 000		24 000
2020-05-22	2020-05-21	4	Hughes Thomas E.	MGEN	Stock Option (right to buy)	A - Award	D	0,63		24 000		24 000
2020-05-22	2020-05-21	4	KOCH KEVIN	MGEN	Stock Option (right to buy)	A - Award	D	0,63		24 000		24 000
2020-05-22	2020-05-21	4	Morris Arlene	MGEN	Stock Option (right to buy)	A - Award	D	0,63		24 000		24 000
2020-05-22	2020-05-21	4	Bowden Christopher	MGEN	Stock Option (right to buy)	A - Award	D	0,63		24 000		24 000
2020-03-17	2020-03-13	4	Leverone Jason A.	MGEN	Stock Option (right to buy)	M - Exercise	D	0,57		−11 249		0
2020-03-17	2020-03-13	4	Leverone Jason A.	MGEN	Common Stock	M - Exercise	D		0,5700	11 249	6		48 829
2020-02-14	2020-02-12	4	Marshall William Stuart	MGEN	Stock Option (right to buy)	A - Award	D	0,80		464 000		464 000
2020-02-14	2020-02-12	4	Leverone Jason A.	MGEN	Stock Option (right to buy)	A - Award	D	0,80		185 000		185 000
2020-02-14	2020-02-12	4	Escolar Diana	MGEN	Stock Option (right to buy)	A - Award	D	0,80		270 000		270 000
2020-02-13	2019-08-21	5	Marshall William Stuart	MGEN	Common Stock	A - Award	D		1,1390	1 250	1		270 646
2020-02-13	2019-02-21	5	Marshall William Stuart	MGEN	Common Stock	A - Award	D		2,4565	1 250	3		269 396
2019-08-23	2019-08-23	4	Leverone Jason A.	MGEN	Stock Option (right to buy)	M - Exercise	D	0,57		−3 093		0
2019-08-23	2019-08-23	4	Leverone Jason A.	MGEN	Common Stock	M - Exercise	D		0,5700	3 093	2		36 330
2019-06-21	2019-06-19	4	Bowden Christopher	MGEN	Stock Option (right to buy)	A - Award	D	2,36		12 000		12 000
2019-06-21	2019-06-19	4	Hatfield Jeffrey S.	MGEN	Stock Option (right to buy)	A - Award	D	2,36		12 000		12 000
2019-06-21	2019-06-19	4	Hughes Thomas E.	MGEN	Stock Option (right to buy)	A - Award	D	2,36		12 000		12 000
2019-06-21	2019-06-19	4	KOCH KEVIN	MGEN	Stock Option (right to buy)	A - Award	D	2,36		12 000		12 000
2019-06-21	2019-06-19	4	Morris Arlene	MGEN	Stock Option (right to buy)	A - Award	D	2,36		12 000		12 000
2019-06-21	2019-06-19	4	TURNER JOSEPH L	MGEN	Stock Option (right to buy)	A - Award	D	2,36		12 000		12 000
2019-04-05	2019-04-03	4	Hughes Thomas E.	MGEN	Stock Option (right to buy)	A - Award	D	2,99		10 106		10 106
2019-02-08	2019-02-06	4	Marshall William Stuart	MGEN	Stock Option (right to buy)	A - Award	D	2,96		232 000		232 000
2019-02-08	2019-02-06	4	Leverone Jason A.	MGEN	Stock Option (right to buy)	A - Award	D	2,96		75 000		75 000
2019-02-08	2019-02-06	4	Levy Adam Scott	MGEN	Stock Option (right to buy)	A - Award	D	2,96		74 000		74 000
2019-02-08	2019-02-06	4	RUBIN PAUL D	MGEN	Stock Option (right to buy)	A - Award	D	2,96		87 000		87 000
2018-10-12	2018-10-11	4	Hughes Thomas E.	MGEN	Common Stock	P - Purchase	D		4,7697	10 000	48		12 827
2018-08-09	2018-08-07	4	Leverone Jason A.	MGEN	Stock Option (right to buy)	M - Exercise	D	0,57		−29 530		0
2018-08-09	2018-08-07	4	Leverone Jason A.	MGEN	Common Stock	M - Exercise	D		0,5700	29 530	17		30 737
2018-06-28	2018-06-27	4	Morris Arlene	MGEN	Stock Option (right to buy)	A - Award	D	6,46		12 000		12 000
2018-06-28	2018-06-27	4	TURNER JOSEPH L	MGEN	Stock Option (right to buy)	A - Award	D	6,46		12 000		12 000
2018-06-28	2018-06-27	4	Booth Bruce	MGEN	Stock Option (right to buy)	A - Award	D	6,46		12 000		12 000
2018-06-28	2018-06-27	4	Bowden Christopher	MGEN	Stock Option (right to buy)	A - Award	D	6,46		12 000		12 000
2018-06-28	2018-06-27	4	Hatfield Jeffrey S.	MGEN	Stock Option (right to buy)	A - Award	D	6,46		12 000		12 000
2018-06-28	2018-06-27	4	Hughes Thomas E.	MGEN	Stock Option (right to buy)	A - Award	D	6,46		12 000		12 000
2018-06-28	2018-06-27	4	KOCH KEVIN	MGEN	Stock Option (right to buy)	A - Award	D	6,46		12 000		12 000
2018-02-15	2018-02-13	4	Marshall William Stuart	MGEN	Stock Option (right to buy)	M - Exercise	D	0,57		−115 818		0
2018-02-15	2018-02-13	4	Marshall William Stuart	MGEN	Common Stock	M - Exercise	D		0,5700	115 818	66		265 646
2018-02-13	2018-02-13	4	Booth Bruce	MGEN	Common Stock	P - Purchase	I		5,5000	545 454	3 000		1 351 090
2018-02-13	2018-02-13	4	Levy Adam Scott	MGEN	Common Stock	P - Purchase	D		5,5000	9 090	50		10 540
2018-02-02	2018-01-31	4	Marshall William Stuart	MGEN	Stock Option (right to buy)	A - Award	D	7,50		245 000		245 000
2018-02-02	2018-01-31	4	RUBIN PAUL D	MGEN	Stock Option (right to buy)	A - Award	D	7,50		85 000		85 000
2018-02-02	2018-01-31	4	Levy Adam Scott	MGEN	Stock Option (right to buy)	A - Award	D	7,50		80 000		80 000
2018-02-02	2018-01-31	4	Leverone Jason A.	MGEN	Stock Option (right to buy)	A - Award	D	7,50		75 000		75 000
2018-01-05	2018-01-03	4	Booth Bruce	MGEN	Stock Option (right to buy)	A - Award	D	9,72		10 191		10 191
2018-01-05	2018-01-03	4	Hughes Thomas E.	MGEN	Stock Option (right to buy)	A - Award	D	9,72		3 426		3 426
2017-12-22	2017-12-20	4	Hughes Thomas E.	MGEN	Common Stock	S - Sale	D		8,0000	−12 000	−96		2 827
2017-06-30	2017-06-28	4	KOCH KEVIN	MGEN	Stock Option (right to buy)	A - Award	D	12,06		12 000		12 000
2017-06-30	2017-06-28	4	LEFKOFF KYLE	MGEN	Stock Option (right to buy)	A - Award	D	12,06		12 000		12 000
2017-06-30	2017-06-28	4	Booth Bruce	MGEN	Stock Option (right to buy)	A - Award	D	12,06		12 000		12 000
2017-06-30	2017-06-28	4	Hughes Thomas E.	MGEN	Stock Option (right to buy)	A - Award	D	12,06		12 000		12 000
2017-06-30	2017-06-28	4	Creecy John W	MGEN	Stock Option (right to buy)	A - Award	D	12,06		12 000		12 000
2017-06-30	2017-06-28	4	TURNER JOSEPH L	MGEN	Stock Option (right to buy)	A - Award	D	12,06		12 000		12 000
2017-06-23	2017-06-22	4	Levy Adam Scott	MGEN	Common Stock	P - Purchase	D		7,5500	200	2		200
2017-03-28	2017-03-24	4	Booth Bruce	MGEN	Stock Option (right to buy)	A - Award	D	11,80		6 844		6 844
2017-03-28	2017-03-24	4	Hughes Thomas E.	MGEN	Stock Option (right to buy)	A - Award	D	11,80		1 191		1 191
2017-03-28	2017-03-24	4	Hughes Thomas E.	MGEN	Common Stock	A - Award	D			778			14 840
2017-03-13	2017-03-10	4	LEFKOFF KYLE	MGEN	Common Stock	S - Sale	I		14,3118	−3 300	−47		463 473
2017-03-13	2017-03-09	4	LEFKOFF KYLE	MGEN	Common Stock	S - Sale	I		14,3846	−2 500	−36		466 773
2017-03-08	2017-03-08	4	LEFKOFF KYLE	MGEN	Common Stock	S - Sale	I		14,7028	−5 000	−74		469 273
2017-03-08	2017-03-06	4	LEFKOFF KYLE	MGEN	Common Stock	S - Sale	I		16,2398	−608	−10		474 273
2017-03-08	2017-03-06	4	LEFKOFF KYLE	MGEN	Common Stock	S - Sale	I		15,7144	−9 392	−148		474 881
2017-02-28	2017-02-28	4	LEFKOFF KYLE	MGEN	Common Stock	S - Sale	I		13,5430	−2 258	−31		484 273
2017-02-28	2017-02-27	4	LEFKOFF KYLE	MGEN	Common Stock	S - Sale	I		13,7910	−1 500	−21		486 531
2017-02-28	2017-02-24	4	LEFKOFF KYLE	MGEN	Common Stock	S - Sale	I		14,0388	−6 500	−91		488 031
2017-02-24	2017-02-23	4	LEFKOFF KYLE	MGEN	Common Stock	S - Sale	I		13,6477	−1 800	−25		494 531
2017-02-24	2017-02-22	4	LEFKOFF KYLE	MGEN	Common Stock	S - Sale	I		14,3554	−4 102	−59		496 331
2017-02-16	2017-02-16	4	RUBIN PAUL D	MGEN	Stock Option (right to buy)	A - Award	D	11,01		87 500		87 500
2017-02-16	2017-02-16	4	Leverone Jason A.	MGEN	Stock Option (right to buy)	A - Award	D	11,01		77 500		77 500
2017-02-16	2017-02-16	4	Marshall William Stuart	MGEN	Stock Option (right to buy)	A - Award	D	11,01		200 000		200 000
2017-02-16	2017-02-16	4	Levy Adam Scott	MGEN	Stock Option (right to buy)	A - Award	D	11,01		87 500		87 500
2017-02-13		3	Creecy John W	MGEN	Common Stock		I						5 413 126
2017-02-13		3	Creecy John W	MGEN	Common Stock		I						5 413 126
2017-02-13		3	Remeditex Ventures LLC	MGEN	Common Stock		D						5 413 126
2017-02-13		3	Remeditex Ventures LLC	MGEN	Common Stock		D						5 413 126
2017-02-13		3	Atlas Venture Fund VII L P	MGEN	Common Stock		D						6 285 160
2017-02-13		3	Atlas Venture Fund VII L P	MGEN	Common Stock		D						6 285 160
2017-02-13		3	LEFKOFF KYLE See Footnotes	MGEN	Common Stock		I						3 715 307
2017-02-13		3	LEFKOFF KYLE See Footnotes	MGEN	Common Stock		I						3 715 307
2017-02-13		3	LEFKOFF KYLE See Footnotes	MGEN	Common Stock		I						2 608 303
2017-02-13		3	LEFKOFF KYLE See Footnotes	MGEN	Common Stock		I						2 608 303
2017-02-13		3	Marshall William Stuart	MGEN	Common Stock		D						297 156
2017-02-13		3	Marshall William Stuart	MGEN	Common Stock		D						297 156
2017-02-13		3	Booth Bruce	MGEN	Common Stock		I						4 753 852
2017-02-13		3	Booth Bruce	MGEN	Common Stock		I						7 090 796
2017-02-13		3	Booth Bruce	MGEN	Common Stock		I						4 753 852
2017-02-13		3	Booth Bruce	MGEN	Common Stock		I						7 090 796
2017-02-13		3	Hughes Thomas E.	MGEN	Common Stock		D						28 124
2017-02-13		3	Hughes Thomas E.	MGEN	Common Stock		D						28 124
2017-02-13	2017-02-13	4	LEBOW BENNETT S	MGEN	Unsecured Demand Promissory Note	M - Exercise	D	5,39				0
2017-02-13	2017-02-13	4	LEBOW BENNETT S	MGEN	Unsecured Demand Promissory Note	A - Award	D	5,39
2017-02-13	2017-02-13	4	LEBOW BENNETT S	MGEN	Common Stock	M - Exercise	D		5,3900	279 067	1 504		280 600
2017-02-08	2017-02-08	4	Gonyer David A	SGNL	Stock Option (Right to Buy)	M - Exercise	D	7,65		−1 200		0
2017-02-08	2017-02-08	4	Gonyer David A	SGNL	Common Stock	M - Exercise	D		7,6500	1 200	9		1 899
2017-02-07	2017-02-03	4	Smith Robin L	SGNL	Stock Option (Right to Buy)	M - Exercise	D	7,65		−1 200		0
2017-02-07	2017-02-03	4	Smith Robin L	SGNL	Common Stock	M - Exercise	D		7,6500	1 200	9		1 900
2017-02-07	2017-02-03	4	LEBOW BENNETT S	SGNL	Stock Option (Right to Buy)	M - Exercise	D	7,65		−1 200		0
2017-02-07	2017-02-03	4	LEBOW BENNETT S	SGNL	Common Stock	M - Exercise	D		7,6500	1 200	9		1 533
2016-11-02	2016-10-31	4	Riccitelli Samuel D	SGNL	Restricted Stock Units	M - Exercise	D	0,00		−200 000		0
2016-11-02	2016-10-31	4	Riccitelli Samuel D	SGNL	Common Stock	F - Taxes	D		0,3600	−103 160	−37		571 370
2016-11-02	2016-10-31	4	Riccitelli Samuel D	SGNL	Common Stock	M - Exercise	D			200 000			674 530
2016-11-02	2016-10-31	4	SEYMOUR TAMARA A	SGNL	Restricted Stock Units	M - Exercise	D			−100 000		0
2016-11-02	2016-10-31	4	SEYMOUR TAMARA A	SGNL	Restricted Stock Units	M - Exercise	D			−46 000		0
2016-11-02	2016-10-31	4	SEYMOUR TAMARA A By Trust	SGNL	Common Stock	F - Taxes	I		0,3600	−45 580	−16		106 447
2016-11-02	2016-10-31	4	SEYMOUR TAMARA A By Trust	SGNL	Common Stock	M - Exercise	I			100 000			152 027
2016-11-02	2016-10-31	4	SEYMOUR TAMARA A By Trust	SGNL	Common Stock	F - Taxes	I		0,3600	−20 967	−8		52 027
2016-11-02	2016-10-31	4	SEYMOUR TAMARA A By Trust	SGNL	Common Stock	M - Exercise	I			46 000			72 994
2016-08-10	2016-08-08	4	SEYMOUR TAMARA A	SGNL	Restricted Stock Units	M - Exercise	D			−23 000		46 000
2016-08-10	2016-08-08	4	SEYMOUR TAMARA A By Trust	SGNL	Common Stock	F - Taxes	I		0,4850	−10 484	−5		26 994
2016-08-10	2016-08-08	4	SEYMOUR TAMARA A By Trust	SGNL	Common Stock	M - Exercise	I			23 000			37 478
2016-06-30	2016-06-28	4	Riccitelli Samuel D	SGNL	Restricted Stock Units	M - Exercise	D	0,00		−124 251		0
2016-06-30	2016-06-28	4	Riccitelli Samuel D	SGNL	Common Stock	F - Taxes	D		0,4600	−64 835	−30		474 530
2016-06-30	2016-06-28	4	Riccitelli Samuel D	SGNL	Common Stock	M - Exercise	D			124 251			539 365
2016-06-20	2016-06-15	4	Gonyer David A	SGNL	Stock Option (Right to Buy)	A - Award	D	0,51		18 000		18 000
2016-06-20	2016-06-15	4	Schuling Douglas A	SGNL	Stock Option (Right to Buy)	A - Award	D	0,51		18 000		18 000
2016-06-20	2016-06-15	4	Smith Robin L	SGNL	Stock Option (Right to Buy)	A - Award	D	0,51		18 000		18 000
2016-06-20	2016-06-15	4	LEBOW BENNETT S	SGNL	Stock Option (Right to Buy)	A - Award	D	0,51		18 000		18 000
2016-05-19	2016-03-28	4	Riccitelli Samuel D	SGNL	Restricted Stock Units	A - Award	D	0,00		200 000		200 000
2016-05-19	2016-03-28	4	SEYMOUR TAMARA A	SGNL	Restricted Stock Units	A - Award	D	0,00		100 000		100 000
2016-02-12	2016-02-11	4	Riccitelli Samuel D	SGNL	Restricted Stock Units	M - Exercise	D	0,00		−124 252		124 251
2016-02-12	2016-02-11	4	Riccitelli Samuel D	SGNL	Common Stock	F - Taxes	D		0,4600	−54 268	−25		415 114
2016-02-12	2016-02-11	4	Riccitelli Samuel D	SGNL	Common Stock	M - Exercise	D			124 252			469 382
2015-11-23	2015-11-20	4	Riccitelli Samuel D	SGNL	Common Stock	P - Purchase	D		0,8000	7 000	6		345 130
2015-11-23	2015-11-19	4	Riccitelli Samuel D	SGNL	Common Stock	P - Purchase	D		0,7800	7 000	5		338 130
2015-08-14	2015-08-12	4	SEYMOUR TAMARA A	SGNL	Employee Stock Option (Right to Buy)	A - Award	D	1,57		60 000		60 000
2015-08-10	2015-08-06	4	Gonyer David A	SGNL	Stock Option (Right to Buy)	A - Award	D	1,62		18 000		18 000
2015-08-10	2015-08-06	4	Gonyer David A	SGNL	Restricted Stock Units	M - Exercise	D			−4 125		0
2015-08-10	2015-08-06	4	Gonyer David A	SGNL	Common Stock	A - Award	D			5 000			10 500
2015-08-10	2015-08-06	4	Gonyer David A	SGNL	Common Stock	M - Exercise	D			4 125			5 500
2015-08-10	2015-08-06	4	Schuling Douglas A	SGNL	Stock Option (Right to Buy)	A - Award	D	1,62		18 000		18 000
2015-08-10	2015-08-06	4	Schuling Douglas A	SGNL	Restricted Stock Units	M - Exercise	D			−4 125		0
2015-08-10	2015-08-06	4	Schuling Douglas A	SGNL	Common Stock	A - Award	D			5 000			10 500
2015-08-10	2015-08-06	4	Schuling Douglas A	SGNL	Common Stock	M - Exercise	D			4 125			5 500
2015-08-10	2015-08-06	4	Smith Robin L	SGNL	Stock Option (Right to Buy)	A - Award	D	1,62		18 000		18 000
2015-08-10	2015-08-06	4	Smith Robin L	SGNL	Restricted Stock Units	M - Exercise	D			−4 125		0
2015-08-10	2015-08-06	4	Smith Robin L	SGNL	Common Stock	A - Award	D			5 000			10 500
2015-08-10	2015-08-06	4	Smith Robin L	SGNL	Common Stock	M - Exercise	D			4 125			5 500
2015-08-10	2015-08-06	4	LEBOW BENNETT S	SGNL	Stock Option (Right to Buy)	A - Award	D	1,62		18 000		18 000
2015-08-10	2015-08-06	4	LEBOW BENNETT S	SGNL	Common Stock	A - Award	D			5 000			5 000
2015-08-05	2015-08-04	4	SEYMOUR TAMARA A	SGNL	Restricted Stock Units	M - Exercise	D			−23 000		69 000
2015-08-05	2015-08-04	4	SEYMOUR TAMARA A	SGNL	Common Stock	F - Taxes	D		1,5600	−8 522	−13		14 478
2015-08-05	2015-08-04	4	SEYMOUR TAMARA A	SGNL	Common Stock	M - Exercise	D			23 000			23 000
2015-07-21	2015-07-17	4	Smith Robin L	SGNL	Restricted Stock Units	M - Exercise	D			−1 375		4 125
2015-07-21	2015-07-17	4	Smith Robin L	SGNL	Common Stock	M - Exercise	D			1 375			1 375
2015-07-21	2015-07-17	4	Schuling Douglas A	SGNL	Restricted Stock Units	M - Exercise	D			−1 375		4 125
2015-07-21	2015-07-17	4	Schuling Douglas A	SGNL	Common Stock	M - Exercise	D			1 375			1 375
2015-07-21	2015-07-17	4	Gonyer David A	SGNL	Restricted Stock Units	M - Exercise	D			−1 375		4 125
2015-07-21	2015-07-17	4	Gonyer David A	SGNL	Common Stock	M - Exercise	D			1 375			1 375
2015-06-23	2015-06-19	4	Riccitelli Samuel D	SGNL	Restricted Stock Units	M - Exercise	D			−124 252		248 503
2015-06-23	2015-06-19	4	Riccitelli Samuel D	SGNL	Common Stock	F - Taxes	D		1,5100	−46 036	−70		331 130
2015-06-23	2015-06-19	4	Riccitelli Samuel D	SGNL	Common Stock	M - Exercise	D			124 252			377 166
2015-04-10	2015-04-08	4	Riccitelli Samuel D	SGNL	Restricted Stock Units	M - Exercise	D			−372 756		372 755
2015-04-10	2015-04-08	4	Riccitelli Samuel D	SGNL	Common Stock	F - Taxes	D		2,0800	−119 842	−249		252 914
2015-04-10	2015-04-08	4	Riccitelli Samuel D	SGNL	Common Stock	M - Exercise	D			372 756			372 756
2014-08-04	2014-08-04	4	SEYMOUR TAMARA A	SGNL	Restricted Stock Units	A - Award	D			92 000		92 000
2014-07-21	2014-07-17	4	Smith Robin L	SGNL	Restricted Stock Units	A - Award	D			5 500		5 500
2014-07-21	2014-07-17	4	Smith Robin L	SGNL	Stock Option (right to buy)	A - Award	D	5,60		6 000		6 000
2014-07-21	2014-07-17	4	Gonyer David A	SGNL	Restricted Stock Units	A - Award	D			5 500		5 500
2014-07-21	2014-07-17	4	Gonyer David A	SGNL	Stock Option (right to buy)	A - Award	D	5,60		6 000		6 000
2014-07-21	2014-07-17	4	Schuling Douglas A	SGNL	Restricted Stock Units	A - Award	D			5 500		5 500
2014-07-21	2014-07-17	4	Schuling Douglas A	SGNL	Stock Option (right to buy)	A - Award	D	5,60		6 000		6 000
2014-06-17		3	LEBOW ALPHA, LLLP By LeBow Alpha, LLLP	SGNL	Common Stock, par value $0.01 per share		I						4 465 258
2014-06-17		3	LEBOW ALPHA, LLLP By LeBow Alpha, LLLP	SGNL	Common Stock, par value $0.01 per share		I						4 465 258
2014-06-17		3	LEBOW ALPHA, LLLP By LeBow Alpha, LLLP	SGNL	Common Stock, par value $0.01 per share		I						4 465 258

Köp på öppna marknaden eller privat köp av icke-derivatsäkerhet

Köp på öppna marknaden eller privat försäljning av icke-derivatsäkerhet

Bevilja, tilldelning eller annat förvärv av värdepapper från företaget (såsom en option)

Omvandling av derivat

Försäljning eller överföring av värdepapper tillbaka til företaget

Betalning av lösenpris eller skatteskuld med del av värdepapper som erhållits från bolaget

Överlåtelse av värdepapper från eller till insidern

Aktieswappar och liknande säkringsaffärer

Utövande eller omvandling av derivatsäkerhet som erhållits från företaget (som en option)

En transaktion friviligt rapporterad på schema 4

Andra (med en fotnot som beskriver transaktionen)

DE:1S1	16,42 €
GB:0K1R	19,55 US$

VRDN / Viridian Therapeutics, Inc. - Insider Trading and Ownership Report - SEC Form 3, 4, 5